STATE-OF-THE-ART PAPER
Structural and Functional Remodeling of the Left AtriumClinical and Therapeutic Implications for Atrial Fibrillation
Grace Casaclang-Verzosa, MD, FPCC,
Bernard J. Gersh, MB, ChB, DPhil, FACC and
Teresa S.M. Tsang, MD, FACC*
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Manuscript received August 30, 2007;
accepted September 26, 2007.
* Reprint requests and correspondence: Dr. Teresa S. M. Tsang, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55901. (Email: tsang.teresa{at}mayo.edu).
Left atrial (LA) structural and functional remodeling reflects a spectrum of pathophysiological changes that have occurred in response to specific stressors. These changes include alterations at the levels of ionic channels, cellular energy balance, neurohormonal expression, inflammatory response, and physiologic adaptations. There is convincing evidence demonstrating an important pathophysiological association between LA remodeling and atrial fibrillation (AF). Measures that will prevent, attenuate, or halt these processes of LA remodeling may have a major public health impact with respect to the epidemic of AF. In this review, we describe the mechanisms involved in LA remodeling and highlight the existing and potential therapeutic options for its reversal, and implications for AF development.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | AF = atrial fibrillation | | ALT-711 = alagebrium chloride | | Ang-II = angiotensin II | | ANP = atrial natriuretic peptide | | BNP = brain natriuretic peptide | | CRP = C-reactive protein | | LA = left atrium/atrial | | LV = left ventricle/ventricular | | MMP = matrix metalloproteinase | | TIMP = tissue inhibitor of metalloproteinase |
|
This article has been cited by other articles:

|
 |

|
 |
 
L. F. Tops, D. W. Den Uijl, V. Delgado, N. A. Marsan, K. Zeppenfeld, E. Holman, E. E. van der Wall, M. J. Schalij, and J. J. Bax
Long-Term Improvement in Left Ventricular Strain After Successful Catheter Ablation for Atrial Fibrillation in Patients With Preserved Left Ventricular Systolic Function
Circ Arrhythm Electrophysiol,
June 1, 2009;
2(3):
249 - 257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Gillis
Angiotensin-Receptor Blockers for Prevention of Atrial Fibrillation -- A Matter of Timing or Target?
N. Engl. J. Med.,
April 16, 2009;
360(16):
1669 - 1671.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Nucifora, J. D. Schuijf, L. F. Tops, J. M. van Werkhoven, S. Kajander, J. W. Jukema, J. H.M. Schreur, M. W. Heijenbrok, S. A. Trines, O. Gaemperli, et al.
Prevalence of Coronary Artery Disease Assessed by Multislice Computed Tomography Coronary Angiography in Patients With Paroxysmal or Persistent Atrial Fibrillation
Circ Cardiovasc Imaging,
March 1, 2009;
2(2):
100 - 106.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Rajappan
Permanent pacemaker implantation technique: part I
Heart,
February 1, 2009;
95(3):
259 - 264.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Gomez, L. Nunez, M. Vaquero, I. Amoros, A. Barana, T. de Prada, C. Macaya, L. Maroto, E. Rodriguez, R. Caballero, et al.
Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1)
Cardiovasc Res,
December 1, 2008;
80(3):
375 - 384.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Y. Qi, Y.-H. Yeh, L. Xiao, B. Burstein, A. Maguy, D. Chartier, L. R. Villeneuve, B. J.J.M. Brundel, D. Dobrev, and S. Nattel
Cellular Signaling Underlying Atrial Tachycardia Remodeling of L-type Calcium Current
Circ. Res.,
October 10, 2008;
103(8):
845 - 854.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Casaclang-Verzosa, M. E. Barnes, and T. S.M. Tsang
Reply.
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2445 - 2445.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Leone, G. Boriani, G. Marinelli, and C. Rapezzi
Local amyloidosis as a possible component of the atrial remodeling accompanying trial.
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2444 - 2445.
[Full Text]
[PDF]
|
 |
|
|